

DAFTAR PUSTAKA

American Diabetes Association. 2014. *Clinical Practice Recommendation: Clinical Use*. 37, suppl.1:S5-13.

(<http://professional.diabetes.org/ResourcesForProfessionals.aspx?cid=84160>)

American Heart Association. Agustus 2015 update. *Cardiovascular Diseases & Diabetes*.

(www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#mainContent).

American Heart Association. Juli 2015 update. *Understand Your Risk of Heart Attacks*. (www.heart.org/HEARTORG/Conditions/HeartAttack/UnderstandYourRiskofHeartAttack/Understand-Your-Risk-of-Heart-Attack_UCM_002040_Article.jsp/#mainContent).

Anderson C, Gaal LV, Caterson ID, Weeke P, James WPT, Coutinho W, Finer N, Sharma AM, Maggioni AP, Torp-Pedersen C. *Relationship Between HbA1c Levels and Risk of Cardiovascular Adverse Outcomes and All-Cause Mortality in Overweight and Obese Cardiovascular High-Risk Women and Men With Type 2 Diabetes*. *Diabetologia* (2012) 55:2348–2355 [doi:10.1007/s00125-012-2584-3]

Association for Clinical Biochemistry. 2012. *HbA1c (Glycated Haemoglobin) (Blood)*.

Badan Penelitian dan Pengembangan Kesehatan Kemenkes RI. 2013. *Riset Kesehatan Dasar (Riskesdas) 2013*.

Booloki HM, Askari A. Agustus 2010. *Acute Myocardial Infarction*.

Coban E, Ozdogan M, Timuragaoglu A. *Effect of Iron Deficiency on The Levels of Hemoglobin A1c in Non-Diabetic Patients*. *Acta Haematol* 2004;112:126-8.

Fajadet J, Wijns W, Laarman G-J. *Randomized, Double-Blind, Multicenter Study of The Endeavor Zotarolimus-Eluting Phosphorylcholine Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of The ENDEAVOR II Trial*. *Circulation* 2006;114:798 – 806.

Gallagher EJ, Roith DL, Bloomgarden Z. *Review of Hemoglobin A1c in The Management of Diabetes*. *Journal of Diabetes* 1(2009):9-17 [doi:10.1111]

- Goto A, Noda M, Matsushita Y, Goto M, Kato M, Isogawa A, Takahashi Y, Kurotami K, Oba S, Nanri A, *et al.* *Hemoglobin A1c Levels and the Risk of Cardiovascular Disease in People Without Known Diabetes: A Population-Based Cohort Study in Japan.* *Med Journal Mei* 2015; 94(17):e785 [doi:10.1097/MD.0000000000000785]
- Hasan SMK, Karim MR, Khan MAR, Chowdhury TA, Asaduzzam A, Ulabbi, MS, Kakoly NS. *Relationship between Haemoglobin A1c and Short Term Outcome in Patients with ST-elevation Myocardial Infraction (STEMI).* *Bangladesh Heart Journal* 2015; 30(1) : 29-32.
- Heianza Y, Arase Y, Kodama S, Hsieh SD, Tsuji H, Hara S, Sone H. *Fasting Glucose and HbA1c Levels as Risk Factors for The Development of Hypertension in Japanese Individuals: Toranomon Hospital Health Management Center Study 16 (TOPICS 16).* *Journal of Human Hypertension* April 2015. 29, 254-259 [doi:10.1038/jhh.2014.77]
- Hsu HP, Jou YL, Lin SJ, Charng MJ, Chen YH, Lee WS, Lu TM, Chen LC, Hsu PF, Huang PH, Leu HB, Wu, TC. *Comparison of In-Hospital Outcome of Acute ST Elevation Myocardial Infarction in Patients with versus without Diabetes Mellitus.* *Acta Cardiol Sin* 2011;27:145-151
- Jousihlati P, Vartiainen E, Tuomilehto J, Puska P. *Sex, Age, Cardiovascular Risk Factors, and Coronary Heart Disease.* *Circ* Maret 1999;99:1165-1172 [doi:10.1161/01.CIR.99.9.1165]
- Kip KE, Hollabaugh KRN, Marroquin OC, William DO. *The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.* *J Am Coll Cardiol* 2008;51:701–7 [doi:10.1016/j.jacc.2007.10.034].
- Lazzeri C, Valente S, Chiostrri M, D’Alfonso MG, Gensini GF. *Clinical significance of glycated hemoglobin in the acute phase of ST elevation myocardial infarction.* *Word J Cardiol* 2014. 6(4): 140-147 [doi:10.4330/wjc.v6.i4.140].
- Lazzeri C, Valente S, Chiostrri M, Attanà P, Mattesini A, Nesti M, Gensini GF. *Glycated Hemoglobin and Long Term Mortality in STEMI Patients.* *JCM*; 2013
- Chan CY, Li R, Chan JYS, Zhang Q, Chan CP, Dong M, Yan BP, Lam Y, Yu CM. *The Value of Admission HbA1c Level in Diabetic Patients with Acute Coronary Syndrome.* *Clin. Cardiol.* 34, 8, 507–512 (2011) [doi:10.1002/clc.20915]

- Liu Y, Yang Y, Zhu J, Tan H, Liang Y, Li J. *Prognostic Significance of Hemoglobin A1c Level in Patients Hospitalized With Coronary Artery Disease. A Systematic Review and Meta-Analysis*. Cardiovasc Diabetol 2011. 10:98.
- Loscalzo J, Antman EM, Braunwald E. 2010. *Harrison's Cardiovascular Medicine, 17th*. The McGraw-Hill Companies; USA.
- Marceau A, Samson JM, Laflamme N, Rinfret S. *Short and Long-Term Mortality after STEMI versus NON-STEMI: A Systematic Review and Meta-Analysis*. J Am Coll Cardiol 2013. 61(10_S) [doi:10.1016/S0735-1097(13)60097-2].
- Martin-Timon I, Collantes CS, Galindo AS, Gomez FJC. *Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?*. World J Diabetes Agustus 2014. 15; 5(4): 444-470 [doi: 10.4239/wjd.v5.i4.444]
- Hartopo AB, Setianto BY, Puspitawati I. 2014, *Kadar Endothelin-1 Plasma sebagai Prediktor Kejadian Buruk Kardiovasikular pada Pasien Infark Miokard Akut*. 2014. Laporan Penelitian Fakultas Kedokteran UGM, Yogyakarta.
- Nakazato R, Arsanjani R, Achenbach S, Gransar H, Cheng VY, Dunning A, *et al*. *Age-Related Risk of Major Adverse Cardiac Event Risk and Coronary Artery Disease Extent and Severity by Coronary CT Angiography: Results From 15187 Patients From The International Multisite*. European Heart Journal-Cardiovascular Imaging 2014;15:586–594 [doi:10.1093/ehjci/jet132]
- Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, Nathan DM. *Effect of Aging on A1c Levels in Individuals Without Diabetes*. Diabetes Care 2008;31:1991-1996 [doi:10.2337]
- Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA, Calles-Escandon J, Russell GB, Freedman BI. *Comparison of Glycated Albumin and Hemoglobin A(1c) Levels in Diabetic Subjects on Hemodialysis*. Kidney Int 2008;73:1062-8 [doi:10.1038/ki.2008.25]
- Rasoul S, Ottervanger JP, Biló HJ, Timmer JR, van 't Hof AW, Dambrink JH, Dikkeschei LD, Hoorntje JC, de Boer MJ, Zijlstra F. *Glucose Dysregulation in Nondiabetic Patients With ST-Elevation Myocardial Infarction: Acute and Chronic Glucose Dysregulation in STEMI*. Neth J Med 2007, 65: 95-100 [PMID: 17387235]
- Skali H, Pfeffer MA, Lubsen J, Solomon SD. *Variable impact of combining fatal and nonfatal end points in heart failure trials*. Circulation. 2006(114), 2298–2304.
- Syed IAA, Khan WA. *Glycated Haemoglobin – a Marker and Predictor of Cardiovascular Diseases*. J Pac Med Assoc Juli 2011. 61(7):690-695.

Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. *Third Universal Definition of Myocardial Infarction*. J Am Coll Cardiol 2012. 60(16):1581-1598.

Tsai ML, Mao CT, Chen DY, Hsieh IC, Wen MS, Chen TH. *Short- and Long-Term Major Cardiovascular Adverse Events in Carotid Artery Interventions: A Nationwide Population Based Cohort Study in Taiwan*. PLoS ONE Maret 2015. 10(3): e0121016 [doi:10.1371/journal.pone.0121016]

Unnikrishnan R, Anjana RM, Mohan V. *Drugs Affecting HbA1c Levels*. Indian J Endocrinol Metab Juli-Agustus 2012. 16(4):528-531 [doi:10.4103]

World Health Organization. 2011 update. Use of Glycated Haemoglobin in the Diagnosis of Diabetes Mellitus.

World Health Organization. Januari 2015 update. Cardiovascular diseases (CVDs). (www.who.int/mediacentre/factsheets/fs317/en/).